Form D · Pharmaceuticals
Olema Pharmaceuticals, Inc.
San Francisco, CA · CIK 0001750284
Offering snapshot reported Dec 12, 2024 · SEC filing
- Reported sold
- $250M Offering amount: $250M
- Investors reported
- 26 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 4, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 12, 2024 | Initial | $249,999,225 | No comparison | 26 | SEC filing |
| Sep 14, 2023 | Initial | $130,000,000 | No comparison | 12 | SEC filing |
| Oct 13, 2020 | Initial | $87,437,914 | No comparison | 27 | SEC filing |
| Jun 23, 2020 | Amendment | $53,900,000 | $23,900,000vs Mar 27, 2020 | 16 | SEC filing |
| Mar 27, 2020 | Initial | $30,000,000 | No comparison | 11 | SEC filing |
| Aug 27, 2018 | Initial | $6,054,922 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $12.5M
- Finders' fees
- $0
- Form D file number
- 021-531835
The Total Offering Amount and Total Amount Remaining to be Sold include amounts that may be received by the Issuer upon exercise of pre-funded warrants at an exercise price of $0.0001 per pre-funded warrant.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Jefferies LLC | 2347 | |
| J.P. Morgan Securities LLC | 79 | |
| Goldman Sachs & Co. LLC | 361 | |
| LifeSci Capital LLC | 168404 | |
| Oppenheimer & Co. Inc. | 249 | |
| H.C. Wainright & Co., LLChow | 375 | |
| Citigroup Global Markets Inc. | 7059 |
Source: Form D, filed Dec 12, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sean Bohen | Director, Executive |
| Sean Bohen, M.D., Ph.D. | Director, Executive |
| Marina Bozilenko | Director |
| Cynthia Butitta | Director |
| Ian Clark | Director |
| Lawrence Fritz | Director |
| Scott Garland | Director |
| Cyrus Harmon | Director, Executive |
| Cyrus L. Harmon, Ph.D. | Director |
| Kinney Horn | Executive |
| Sandra Horning, M.D. | Director |
| Gorjan Hrustanovic | Director |
| Gorjan Hrustanovich | Director |
| Gorjan Hrustanovic, Ph.D. | Director |
| Pamela Klein | Executive |
| Shane Kovacs | Executive |
| Peter Kusher | Director, Executive |
| Peter Kushner | Executive |
| Yi Larson | Director |
| Andrei Manoliu | Director |
| Frank Mc Cormick | Director |
| John Moriarty | Executive |
| David Myles | Executive |
| David C. Myles, Ph.D. | Executive |
| Andrew Rappaport | Director |
| Graham Walmsley | Director |
| Graham Walmsley, M.D., Ph.D. | Director |
| Naseem Zojwalla, M.D. | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
780 Brannan Street
San Francisco, CA, 94103
San Francisco, CA, 94103